Douglas Feltner

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. pmc Psychometric evaluation of a visual analog scale for the assessment of anxiety
    Valerie S L Williams
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC 27707, USA
    Health Qual Life Outcomes 8:57. 2010
  2. doi Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid
    Douglas E Feltner
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Psychopharmacol 25:763-73. 2011
  3. ncbi A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder
    Douglas E Feltner
    Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Clin Psychopharmacol 23:240-9. 2003
  4. doi Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial
    Douglas Feltner
    Pfizer Global Research and Development, MS 6025 B2234, New London, CT 06320, USA
    J Psychiatr Res 43:1224-30. 2009
  5. doi Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder
    Douglas E Feltner
    Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    CNS Neurosci Ther 15:12-8. 2009
  6. ncbi Long-term efficacy of pregabalin in generalized anxiety disorder
    Douglas Feltner
    Pfizer Global Research and Development, Ann Arbor, Missouri, USA
    Int Clin Psychopharmacol 23:18-28. 2008
  7. ncbi Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder
    Robert J Morlock
    Pfizer Inc, Global Research and Development, Ann Arbor, MI, USA
    J Psychiatr Res 42:1024-36. 2008
  8. ncbi Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission
    David J Dooley
    Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Trends Pharmacol Sci 28:75-82. 2007
  9. doi A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
    Brendon Binneman
    Pfizer Global Research and Development, M S 8260 2604, Groton, CT 06340, USA
    Am J Psychiatry 165:617-20. 2008
  10. ncbi How modeling and simulation have enhanced decision making in new drug development
    Raymond Miller
    Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA
    J Pharmacokinet Pharmacodyn 32:185-97. 2005

Detail Information

Publications15

  1. pmc Psychometric evaluation of a visual analog scale for the assessment of anxiety
    Valerie S L Williams
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC 27707, USA
    Health Qual Life Outcomes 8:57. 2010
    ..Measuring early onset, however, requires a sensitive and clinically responsive tool. This study evaluates the psychometric properties of a patient-reported Global Anxiety-Visual Analog Scale (GA-VAS)...
  2. doi Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid
    Douglas E Feltner
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Psychopharmacol 25:763-73. 2011
    ..For the doses studied, the rank order of statistically significant findings suggestive of abuse potential was diazepam (9/10 measures significant) > levetiracetam (6/10) > diphenhydramine (5/10) > valproic acid (2/10)...
  3. ncbi A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder
    Douglas E Feltner
    Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Clin Psychopharmacol 23:240-9. 2003
    ..This study supports the hypothesis that pregabalin is effective and safe in short-term therapy for GAD. More studies are needed to determine the best dosing regimen to optimize efficacy and tolerability...
  4. doi Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial
    Douglas Feltner
    Pfizer Global Research and Development, MS 6025 B2234, New London, CT 06320, USA
    J Psychiatr Res 43:1224-30. 2009
    ..Excluding these 56 patients from the analysis resulted in a greater separation of active treatment from placebo. The PRSS is a promising tool for predicting placebo response in clinical trials and requires further use and validation...
  5. doi Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder
    Douglas E Feltner
    Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA
    CNS Neurosci Ther 15:12-8. 2009
    ..Rapid onset of symptomatic improvement is a desirable characteristic of new generalized anxiety disorder (GAD) treatments. A validated rating scale is needed to assess GAD symptoms during the first days of treatment...
  6. ncbi Long-term efficacy of pregabalin in generalized anxiety disorder
    Douglas Feltner
    Pfizer Global Research and Development, Ann Arbor, Missouri, USA
    Int Clin Psychopharmacol 23:18-28. 2008
    ..2%), headache (10.1 vs. 11.2%), and somnolence (6.0 vs. 0%). No safety concerns were identified with long-term treatment. The study indicates that pregabalin is an effective treatment for the prevention of relapse in patients with GAD...
  7. ncbi Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder
    Robert J Morlock
    Pfizer Inc, Global Research and Development, Ann Arbor, MI, USA
    J Psychiatr Res 42:1024-36. 2008
    ....
  8. ncbi Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission
    David J Dooley
    Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Trends Pharmacol Sci 28:75-82. 2007
    ..This modulation is characterized by a reduction of the excessive neurotransmitter release that is observed in certain neurological and psychiatric disorders...
  9. doi A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
    Brendon Binneman
    Pfizer Global Research and Development, M S 8260 2604, Groton, CT 06340, USA
    Am J Psychiatry 165:617-20. 2008
    ..This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder...
  10. ncbi How modeling and simulation have enhanced decision making in new drug development
    Raymond Miller
    Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA
    J Pharmacokinet Pharmacodyn 32:185-97. 2005
    ....
  11. ncbi Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005
    ..Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord...
  12. ncbi Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing
    Robert B Pohl
    University Psychiatric Center, Wayne State University, Detroit, MI 48207, USA
    J Clin Psychopharmacol 25:151-8. 2005
    ..This study demonstrates that pregabalin is an effective treatment of generalized anxiety disorder, with BID dosing showing similar efficacy and comparable tolerability with TID dosing...
  13. ncbi Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study
    Atul C Pande
    Pfizer Global Research and Development, New London, CT 06320, USA
    J Clin Psychopharmacol 24:141-9. 2004
    ..Somnolence and dizziness were the most frequently occurring adverse events among patients receiving pregabalin 600 mg/d. In conclusion, pregabalin 600 mg/d was an effective and well-tolerated treatment of social anxiety disorder...
  14. ncbi Incorporating the assessment of abuse liability into the drug discovery and development process
    Robert S Mansbach
    Worldwide Regulatory Affairs, Pfizer Global Research and Development, 50 Pequot Avenue, MS6025 B2170, New London, CT 06320, USA
    Drug Alcohol Depend 70:S73-85. 2003
    ..The emerging properties of the product will define the unique procedures best applied to assess it...
  15. ncbi Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003
    ..Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder...